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a b s t r a c t
Ankylosing spondylitis (AS) is an inflammatory disorder that presents with arthritis of 
the axial skeleton, including sacroiliac joints. Vitamin D is a secosteroid hormone with 
a long-established role in calcium and phosphate homeostasis, and in the regulation of 
bone formation and resorption. It is now known that vitamin D plays an immunosuppres-
sive role in the body, and there is interest of late in the role of vitamin D in autoimmune 
diseases. Inflammation may be responsible for some of the loss of bone mineral densi-
ty seen in AS. We reviewed the literature for studies assessing vitamin D level as a ma-
rker of AS disease activity and those examining vitamin D levels in AS in comparison to 
healthy controls. Four of 7 studies found a significant negative correlation between vitamin 
D levels and Bath Ankylosing Spondylitis Index (BASDAI), erythrocyte sedimentation rate 
(ESR) and C-reactive protein (CRP). In a review of 8 case-control studies, the mean level of 
25-hydroxyvitamin D3 was 22.8 ± 14.1 ng/mL in 555 AS patients versus 26.6 ± 12.5 ng/mL in 
557 healthy controls. When compared with a 2-sample t test, vitamin D levels were signi-
ficantly higher in healthy controls (p < 0.01). We conclude that patients with AS appear to 
have lower vitamin D levels versus healthy controls; however, the cause is unclear. Existing 
studies do not demonstrate a consistent link between vitamin D levels and disease activity 
in AS. Further studies are in need to determine if a causative link exists between vitamin 
D deficiency and AS.
© 2014 Sociedade Brasileira de Reumatologia. Published by Elsevier Editora Ltda. 
All rights reserved.
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Níveis de vitamina D na espondilite anquilosante: a deficiência 
corresponde à atividade da doença?
Palavras-chave:
Espondilite anquilosante 
Vitamina D
Autoimune
Inflamação
BASDAI
r e s u m o
A espondilite anquilosante (EA) é um transtorno inflamatório que se apresenta com artrite 
da coluna vertebral, inclusive das articulações sacroilíacas. A vitamina D é um hormônio 
secosteroide com papel consagrado na homeostase do cálcio e do fosfato e na regulação da 
formação e reabsorção óssea. Atualmente, sabe-se que a vitamina D desempenha um papel 
imunossupressivo no organismo, e ultimamente tem havido interesse no papel dessa vi-
tamina em doenças autoimunes. A inflamação pode ser responsável por parte da perda da 
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densidade mineral óssea observada em pacientes com EA. Revisamos a literatura em busca 
de estudos que avaliassem os níveis de vitamina D em pacientes com EA, em comparação 
com controles saudáveis. Quatro dos sete estudos chegaram a uma significativa correlação 
negativa entre os níveis de vitamina D e o instrumento Bath Ankylosing Spondylitis Index 
(BASDAI), velocidade de hemossedimentação (VHS) e proteína C reativa (PCR). Em uma re-
visão de oito estudos de caso-controle, o nível médio de 25-hidroxivitamina D3 foi 22,8 ± 
14,1 ng/mL em 555 pacientes com EA versus 26,6 ± 12,5 ng/mL em 557 controles saudáveis. 
Quando comparados com um teste t para duas amostras, os níveis de vitamina D estavam 
significativamente mais altos em controles saudáveis (p <0,01). Concluímos que pacientes 
com EA parecem ter níveis de vitamina D mais baixos versus controles saudáveis, mas a 
causa desse achado ainda não foi esclarecida. Os estudos já publicados não demonstram 
uma ligação consistente entre níveis de vitamina D e atividade da doença em pacientes 
com EA. Há necessidade de mais estudos que determinem se existe um elo causal entre 
deficiência de vitamina D e EA.
© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. 
Todos os direitos reservados.
Introduction
Ankylosing spondylitis (AS) is an inflammatory disorder of un-
known cause that features arthritis of the spine and sacroiliac 
joints, oligoarthritis of peripheral joints, and inflammation of 
tendons, ligaments, and joint capsule insertion sites. The on-
set of the disease usually begins in the second or third decade 
of life with a male to female prevalence of 3:1.1 Patients gen-
erally experience a gradual onset of back stiffness and pain 
radiating to the buttocks with symptoms progressing in an 
ascending fashion. Peripheral arthritis of hips, shoulders and 
knees may be transient or permanent. Advanced disease can 
involve fusion of the entire spine. AS is correlated with HLA-
B27 antigen positivity, and patients test negative for serum 
rheumatoid factor and anti-cyclic citrullinated peptide (anti-
CCP) antibodies. Disease activity in AS can be measured with 
non-specific inflammatory serum markers, such as C-reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR), or 
with a standardized questionnaire such as the bath ankylos-
ing spondylitis disease activity index (BASDAI).
Vitamin D is a secosteroid hormone with a well-estab-
lished role in calcium and phosphate homeostasis, and in 
the regulation of bone formation and resorption, however it 
is now known that vitamin D is much broader. Studies have 
shown vitamin D functions as an endogenous immunomodu-
lator. Vitamin D alters gene expression that affects cellular 
functions, such as apoptosis, differentiation, and prolifera-
tion.2 Alterations in vitamin D receptors have been linked to 
autoimmune conditions, with some studies suggesting an 
association between vitamin D deficiency and autoimmune 
disease.3 As such, there has been increasing interest in study-
ing vitamin D levels in patients with autoimmune conditions.
Osteoporosis is a well-known feature of AS, and studies 
have suggested that lower bone mineral density and high-
er bone turnover may be related to inflammation.4 Thus it 
stands to reason that vitamin D levels may bear some relation 
to disease activity in AS. There have been a handful of clinical 
investigations over the last 20 years looking at what role vita-
min D, or deficiency thereof, may play in AS. The aim of this 
review study is to summarize this research and to address 
two questions. First, do serum 25-hydroxyvitamin D3 levels 
correspond to disease activity in patients with AS? Second, 
is there any difference between serum 25-hydroxyvitamin D3 
levels in patients with AS when compared to healthy control 
subjects?
Methods
A literature search was ran using the PubMed and Embase 
databases for English language peer-reviewed papers that ex-
amined either serum vitamin D levels in AS patients as com-
pared to healthy controls, or the correlation between vitamin 
D levels in AS patients and disease activity. The keywords “vi-
tamin D” and “ankylosing spondylitis” were used. All refer-
ences cited by these papers were reviewed to locate addition-
al studies not referenced in the aforementioned databases. 
Single case reports, review articles and studies that included 
patients with other autoimmune conditions other than AS in 
their analyses were excluded.
We identified 11 studies in total meeting these criteria,4-12 
among those, 8 were case-control studies, and 3 were case-
only cross-sectional studies.
Vitamin D levels and disease activity
To evaluate the relationship between vitamin D levels and 
measures of disease activity, both cross-sectional and case-
control studies were reviewed. Of the 11 studies that were re-
trieved, 7 studies examined the correlation between vitamin 
D levels and indicators of disease activity in AS. This included 
6 suitable case-control studies and 1 cross-sectional case-
only study. Collectively, this represented 573 patients, 82% of 
whom were male, with a mean age of 38.9 years.
The most common indicators of disease activity used were 
the bath ankylosing spondylitis index (BASDAI), erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). All 
studies used the Spearman correlation coefficient to study 
the relationship between variables. For the purposes of this 
analysis, p<0.05 was taken as statistically significant. All 
studies compared disease activity with serum levels of 25-hy-
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droxyvitamin D3, except for the two studies by Lange that 
measured serum 1,25-dihydroxyvitamin D3 levels.
4-5 The re-
sults are summarized in Table 1.
Four of 7 studies (encompassing 52% of the total patients) 
found a significant negative correlation between BASDAI and 
vitamin D levels, while the other 3 studies did not find a sig-
nificant association. Significant negative correlations with 
vitamin D levels were noted for both ESR and CRP in 4 of 7 
studies (encompassing 48% of total patients).
Vitamin D levels in ankylosing spondylitis
Eight case-control studies that compared vitamin D levels in a 
total of 555 AS patients and 557 healthy controls were identi-
fied. The mean age of these patients was 39.4 years, and 78.0% 
were male. Results are summarized in Table 2. The study by 
Yazmalar et al. studied vitamin D levels over summer and 
winter in the same set of patients.11 As the vitamin D levels 
did not vary significantly between seasons, they were aver-
aged.
Five of 8 studies found that patients with AS had signifi-
cantly lower vitamin D levels than controls, while 3 studies 
found no significant difference. The average 25-hydroxyvi-
tamin D level over all studies was (22.8r14.1) ng/mL in AS 
patients and (26.6r12.5) ng/mL in healthy controls. When 
compared with a 2-sample t test, the vitamin D levels were 
significantly higher in healthy controls (3.8r0.8 ng/mL, 
p<0.01). Only 6 of 8 studies compared ESR and CRP between 
healthy subjects and those with AS, but the serum levels of 
both markers were found to be significantly higher in patients 
with AS in all 6 of these studies.
Discussion
The vitamin D receptor gene is expressed in many immune 
cells.13 Vitamin D regulates both innate and adaptive immu-
nity suppressing adaptive immunity (B and T lymphocyte 
functions) and potentiates the innate response (monocytes, 
macrophages and antigen presenting cells).14 The first aim of 
this review was to examine existing studies in order to de-
termine if vitamin D levels in patients with AS correspond to 
disease activity.
The activity of many rheumatological diseases including 
AS can be measured with CRP and ESR, which are non-spe-
cific but provide some objective indication of inflammation. 
Several newer biomarkers which hope to offer better speci-
ficity are under investigation including matrix metallopro-
teinases (MMP-3), type II collagen epitopes, and interleukin-6 
(IL-6).15 The bath ankylosing spondylitis disease activity index 
(BASDAI) was developed in 1994 and provides a standardized 
method of assessing disease activity as it relates to patients’ 
symptoms and quality of life. Although some newer models 
have been developed, BASDAI remains the most widely-used 
tool to assess disease activity in patients with AS.16 
The studies in this analysis had conflicting data regarding 
the correlation of vitamin D levels with ESR, CRP and BASDAI 
scores. Also of note, most of the statistically significant correla-
tions were weak (r2<0.6). The existing studies are inconclusive 
as to whether serum vitamin D levels bear any significant cor-
relation to systemic inflammation or disease activity in patients 
with AS. This echoes what has been seen in similar studies look-
ing at activity of other rheumatological diseases.3 The results in 
the literature are mixed, with some of studies finding an asso-
ciation between vitamin D levels and disease activity in SLE and 
RA, and other studies unable to reproduce these results. 
The next question which we sought to address was wheth-
er vitamin D levels were different in patients with AS. Vita-
min D insufficiency has been described as a pandemic, with 
as many as one billion people worldwide insufficient or defi-
cient in vitamin D.17 There is no universal consensus on what 
constitutes an ideal serum level of 25-hydroxyvitamin D3. In a 
2011 clinical practice guideline, the Endocrine Society stated 
an ideal serum level would be at least 30 ng/mL (75 nmol/L).18 
Serum levels between 21-29 ng/mL are defined as vitamin D 
insufficiency, and levels 20 ng/mL or below are considered vi-
tamin D deficiency. 
When data among the 8 studies we reviewed were pooled, 
it was found that patients with AS have significantly lower 
vitamin D levels as compared to healthy controls. The average 
vitamin D levels among AS patients in all 8 studies were in-
sufficient or deficient. It is also interesting to note that mean 
vitamin D levels were also insufficient in the healthy controls 
in 5 of 8 studies. 
Overall, the findings correspond with other cross-sectional 
studies which showed that deficient serum levels of vitamin 
Table 1 – Correlation between vitamin D levels and disease activity in ankylosing spondylitis patients
First Author Patients Age (years) Male % R2 Vit D vs. BASDAI r2 Vit D vs. VHS r2 Vit D. vs. PCR
Lange, 20054 58 38.4a 65.5 -0.567 -0.57 -0.702
Lange, 20015 70 38.4a 68.6 -0.547 -0.547 -0.711
Mermerci Baskan, 20106 100 39.9 ± 10.9 75.0 NS NS NS
Arends, 20117 128 41 ± 11.0 93.0 NS NS NS
Durmus, 20128 99 36.8 ± 10.8 84.8 -0.304 -0.366 -0.344
Erten, 20139 48 35.5 ± 10.0 79.2 NS -0.428 -0.592
Hmamouchi, 201310 70 40.0 ± 12.0 100 -0.32 NS NS
573 38.9b 82.4%b
AS, ankylosing spondylitis; BASDAI, bath ankylosing spondylitis index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; Vit D, 
25-hydroxyvitamin D; NS, no significant correlation
aStandard deviation not reported
bWeighted average
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D (<20 ng/mL) are present in a significant percentage of pa-
tients with autoimmune diseases such as diabetes mellitus 
type 1,19 systemic lupus erythematosus and rheumatoid ar-
thritis (RA).20 As pointed out by Welsh et al.21 in a review of 
vitamin D levels and RA, the cross-sectional studies included 
in this analysis are limited as they cannot rule out reverse 
causality. Thus, with the existing studies it is not possible to 
ascertain whether vitamin D deficiency is a cause, or a con-
sequence, of AS. 
Tumor necrosis factor alpha (TNF-α) is thought to play a 
role in chronic inflammation, and it is known to inhibit the 
binding of the vitamin D receptor to vitamin D responsive el-
ement (VDRE) of the osteocalcin gene. It may down-regulate 
the 24-hydroxylase activity in kidneys, possibly reducing vi-
tamin D levels.8 There has been some suggestion in the lit-
erature that vitamin D, as with other circulating vitamins, 
may be subject to an inverse acute phase response.22 In other 
words, systemic inflammation may lower circulating levels of 
vitamin D.
On the other hand, vitamin D has been reported to inhibit 
expression of TNF-α,23 and it follows that vitamin D deficiency 
may accelerate inflammation. Lange et al. noted a negative 
correlation between vitamin D levels and TNF-α in patients 
with AS.4 Prospective studies suggest vitamin D deficiency 
is associated with an increased risk of RA development.24 
Well-designed prospective studies are required to determine 
whether vitamin D status has any relationship to the develop-
ment of AS. 
There are several possible explanations of the heterogene-
ity in the results. The studies used in this analysis had differ-
ent sizes and statistical powers, and varied in their control of 
confounding factors. All these studies reported exclusion of 
patients with chronic and systemic diseases, but use of glu-
cocorticoids, biological agents, bisphosphonates, and vitamin 
D supplementation itself was not controlled in all of them. 
The studies had differing percentages of male and female pa-
tients, and seasonality was not controlled in of those. Yazma-
lar et al. have found that although circulating levels of 25(OH) 
vitamin D do not vary significantly over the seasons, BASDAI 
scores are higher in winter months.11 It is also known that 
circulating vitamin D levels are affected by body mass index, 
skin pigmentation, latitude, clothing and sunscreen use,25 and 
it is not clear whether all of these studies controlled for these 
confounders. 
Conclusion
In conclusion, patients with AS, as in other autoimmune dis-
eases, appear to have lower vitamin D levels than healthy con-
trols, however the cause is unclear. In studies to date, there has 
been no consistent link between vitamin D levels and disease 
activity in AS, neither evidence at this point that would justify 
the use of serum 25-hydroxyvitamin D3 levels as a marker of 
disease activity. It remains to be seen whether vitamin D defi-
ciency can predispose to the development of AS and if mainte-
nance of optimal vitamin D levels can improve outcomes in AS.
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